Stocktoria
Wave Life Sciences Ltd. WVE
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2015-11-11
Wave Life Sciences Ltd. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $42.7M | $108.3M | $113.3M | $3.6M | $41.0M |
| R&D expense | $182.8M | $159.7M | $130.0M | $115.9M | $121.9M |
| Operating income | -$215.4M | -$110.4M | -$68.0M | -$162.7M | -$127.0M |
| Income tax | $0 | $0 | -$677,000 | $681,000 | -$204,000 |
| Net income | -$204.4M | -$97.0M | -$57.5M | -$161.8M | -$122.2M |
| EPS (diluted) | $-1.21 | $-0.70 | $-0.54 | $-2.05 | $-2.36 |
| Operating cash flow | -$187.5M | -$151.0M | -$19.4M | -$127.8M | -$89.0M |
| Free cash flow | -$188.2M | -$152.0M | -$20.5M | -$129.1M | -$89.6M |
| Cash & equivalents | $602.1M | $302.1M | $200.4M | $88.5M | $150.6M |
| Total assets | $638.5M | $352.2M | $274.9M | $146.4M | $207.0M |
| Total liabilities | $112.3M | $134.8M | $227.4M | $183.6M | $166.6M |
| Shareholders' equity | $518.4M | $209.5M | $39.6M | -$45.1M | $32.5M |
Source: SEC EDGAR filings · CIK 0001631574 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.